Business Context and Reporting Period
This Form 8-K Current Report was filed by Artiva Biotherapeutics, Inc. on February 18, 2026. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation matters rather than financial performance.
Material Changes
The primary material change reported is the appointment of Elaine Sorg as a Class I director of the Company, effective February 18, 2026. Her term will expire at the 2028 annual meeting of stockholders.
Management Commentary, Risks, and Unusual Items
Director Appointment and Background
Elaine Sorg brings over 35 years of senior executive experience in the pharmaceutical industry, including roles at AbbVie and Eli Lilly. She previously served as Senior Vice President and President of AbbVie's U.S. commercial operations until her retirement in January 2024. She currently serves as a director of CSL Limited and as a Senior Advisor at the Boston Consulting Group.
Compensatory Arrangements
- Annual Cash Retainer: $40,000 for service on the Board.
- Initial Option Grant: 27,500 shares of common stock granted on the date of appointment.
- Vesting Schedule: One-third of the initial grant vested immediately; the remainder vests monthly over two years, subject to continuous service.
- Future Grants: Automatic annual option grants of 13,750 shares on the date of each annual meeting, vesting in full after one year or at the next annual meeting.
- Change in Control: All option grants vest in full upon a change in control.
The filing states there are no transactions in which Ms. Sorg has an interest requiring disclosure under Item 404(a) of Regulation S-K, and no arrangements with other persons influenced her selection.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 27,500 share option grant.
- Confirm the total number of outstanding shares and the potential dilution impact of future annual grants.
- Review the Company's 2024 Equity Incentive Plan for specific definitions of "continuous service" and "change in control."
- Check for any subsequent filings regarding Ms. Sorg's committee assignments on the Board.